KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Revenue (2019 - 2025)

Aurinia Pharmaceuticals' Revenue history spans 7 years, with the latest figure at $77.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 28.81% year-over-year to $77.1 million; the TTM value through Dec 2025 reached $283.1 million, up 20.38%, while the annual FY2025 figure was $283.1 million, 20.38% up from the prior year.
  • Revenue reached $77.1 million in Q4 2025 per AUPH's latest filing, up from $73.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $77.1 million in Q4 2025 to a low of $914000.0 in Q1 2021.
  • Average Revenue over 5 years is $43.7 million, with a median of $47.7 million recorded in 2023.
  • Peak YoY movement for Revenue: surged 50475.86% in 2021, then decreased 2.27% in 2023.
  • A 5-year view of Revenue shows it stood at $23.4 million in 2021, then grew by 21.5% to $28.4 million in 2022, then surged by 58.59% to $45.1 million in 2023, then surged by 32.76% to $59.9 million in 2024, then rose by 28.81% to $77.1 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Revenue are $77.1 million (Q4 2025), $73.5 million (Q3 2025), and $70.0 million (Q2 2025).